Biological activity of Imidazo-thiazole scaffolds: A comprehensive review of 2020–2025 advances

The imidazo-thiazole fused heterocycle has emerged as a versatile and privileged scaffold in drug discovery owing to its favorable physicochemical properties, synthetic accessibility and capacity for extensive substitution. This review synthesizes quantitative evidence on the biological performance of imidazo-thiazole scaffolds and closely related benzo- and fused analogues reported between 2020 and 2025. Across therapeutic categories—including antitubercular, anticancer, antimicrobial, antiviral, antioxidant, and enzyme-inhibitory activity—the compiled studies consistently relate measurable potency (e.g., MIC/IC 50 ranges reported for target engagement and cellular assays) to systematic structure–activity relationships. In antitubercular investigations, several lead series demonstrate sub-micromolar to low-micromolar activity against Mycobacterium tuberculosis , accompanied by pharmacokinetic and tolerability data in relevant preclinical settings, strengthening the case for target engagement and translational feasibility. For enzyme and pathway modulation, the activity landscape covers clinically relevant targets (e.g., BRAF, IDO1, α-glucosidase), showing how substituent electronics, steric features, and lipophilicity govern potency and selectivity. Collectively, the review provides a data-grounded framework for medicinal-chemistry optimization of the imidazo-thiazole core, highlighting opportunities and research gaps for advancing these scaffolds toward next-generation therapeutic candidates.